ResearcherArmy Medical UniversityNo recent work listed

Anbin Wang

Provisional: name at one institution (moderate confidence, 0.60), identity_conf@1As of 7 November 2026

Known by name at one institution; no external author ID yet. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2019: 1 paper

Papers 1

ANLN-induced EZH2 upregulation promotes pancreatic cancer progression by mediating miR-218-5p/LASP1 signaling axis. Co-author DOI 10.1186/s13046-019-1340-7 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Wei Liu · 1 shared paper, 2019 · strength 0.10
- Paper ANLN-induced EZH2 upregulation promotes pancreatic cancer progression by mediating miR-218-5p/LASP1 signaling axis. DOI 10.1186/s13046-019-1340-7 ↗
Ping Bie · 1 shared paper, 2019 · strength 0.10
- Paper ANLN-induced EZH2 upregulation promotes pancreatic cancer progression by mediating miR-218-5p/LASP1 signaling axis. DOI 10.1186/s13046-019-1340-7 ↗
Haisu Dai · 1 shared paper, 2019 · strength 0.10
- Paper ANLN-induced EZH2 upregulation promotes pancreatic cancer progression by mediating miR-218-5p/LASP1 signaling axis. DOI 10.1186/s13046-019-1340-7 ↗
Yi Gong · 1 shared paper, 2019 · strength 0.10
- Paper ANLN-induced EZH2 upregulation promotes pancreatic cancer progression by mediating miR-218-5p/LASP1 signaling axis. DOI 10.1186/s13046-019-1340-7 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.